Download PDFPDF

Chemotherapy for advanced lung cancer: is the glass half full or half empty?
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Using the Number Needed to Treat to Make Decisions About Chemotherapy for Lung Cancer

    Dear Editor

    Like Dr. Silvestri, I support a model of shared decision making when considering chemotherapy [1]. Unfortunately, many patients don’t realize that the advantages of chemotherapy are not shared equally by those treated. For example, Spiro et al. show that chemotherapy reduces the risk of death from lung cancer by 9% and 5% at one and two years, respectively [2]. The fact that the reduction benefits o...

    Show More
    Conflict of Interest:
    None declared.